[1]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250-254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250-254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
点击复制

预防非瓣膜性心房颤动性脑卒中的治疗新进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年3期
页码:
250-254
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation
作者:
胡红玲1; 综述; 罗素新1; 2; 审校
1.重庆医科大学研究生院,重庆 400016; 2.重庆医科大学附属第一医院心内科,重庆 400016
Author(s):
HU Hongling1; LUO Suxin1; 2
1.Chongqing Medical University Graduate School,Chongqing 400016,China; 2. Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China
关键词:
心房颤动;  脑卒中;  华法林;  新型口服抗凝药;  经皮左心耳封堵术;  左心耳封堵系统
Keywords:
Atrial fibrillation;  Stroke;  Warfarin;  New oral anticoagulants;  Percutaneous left atrial appendage occlusion;  WATCHMAN
分类号:
R541.7; R743.3
DOI:
10.16806/j.cnki.issn.1004-3934.2016.03.009
文献标志码:
A
摘要:
心房颤动是临床最常见的心律失常,所致的脑卒中具有高致死率和致残率的特点。近年来非瓣膜性心房颤动患者脑卒中的预防已得到高度关注,但收效不明显。最经典的预防心房颤动性脑卒中的方法为口服华法林抗凝治疗,但因其治疗窗窄,需频繁监测国际标准化比值等,使用受限。新型口服抗凝药弥补了华法林的部分不足,但并非所有患者都能耐受或有效。对于不能口服或口服药物无效的患者,需要新方法来预防脑卒中,经皮左心耳封堵术为其带来了新希望。现就预防非瓣膜性心房颤动性脑卒中的各种方法进行综述。
Abstract:
Atrial fibrillation is the most common arrhythmia in clinic,and easily leads to stroke,which has high mortality and morbidity.In recent years,we have attached great importance to the prevention of stroke in patients with atrial fibrillation, but the effect was not obvious.The gold standard in prevention is oral warfarin anticoagulant therapy, and its use is limited for warfarin's narrow therapeutic window, and frequent monitoring of INR values.New oral anticoagulants(NOAC)make up for the inadequacy of warfarin, but not all patients are effective.For these patients, the percutaneous left atrial appendage occlusion has brought us new hope. This paper reviews the therapeutic advances of preventing the stroke in patients with atrial fibrillation.

参考文献/References:

[1] 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志, 2004, 43(7): 491-494.
[2] Wolf PA,Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study[J]. Stroke,1991,22(8):983-988.
[3] Hart RG,Pearce LA,Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007,146(12):857-867.
[4] 黄从新,张澍,马长生.心房颤动: 目前的认识和治疗建议[J].中华心律失常学杂志,2012,16(4):246-289.
[5] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151.
[6] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2013,369(22):2093-2104.
[7] Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation:a net clinical benefit analysis using a ‘real world' nationwide cohort study[J]. Thromb Haemost, 2011,106(4):739.
[8] Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants(dabigatran,rivaroxaban,apixaban)versus no treatment in a ‘real world' atrial fibrillation population:a modelling analysis based on a nationwide cohort study[J]. Thromb Haemost,2012,107(3):584-589.
[9] Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365:981-992.
[10] Patel MR,Mahaffey KW,Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,365(10):883-891.
[11] Lewalter T, Kanagaratnam P, Schmidt B, et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk:opportunities and challenges for percutaneous left atrial appendage occlusion[J]. Europace,2014,16(5): 626-630.
[12] Lewalter T, Ibrahim R, Albers B, et al. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation[J]. Europace,2013,15(5):652-656.
[13] Sievert H,Lesh MD,Trepels T,et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation early clinical experience[J]. Circulation,2002,105(16):1887-1889.
[14] Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation:results from the international multi-center feasibility trials[J]. J Am Coll Cardiol,2005,46(1):9-14.
[15] Matsumoto T,Kar S. Latest advances in transseptal structural heart interventions:percutaneous mitral valve repair and left atrial appendage occlusion[J]. Circ J,2014,78(8):1782-1790.
[16] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial[J]. Lancet,2009,374(9689): 534-542.
[17] Reddy VY,Holmes D,Doshi SK,et al. Safety of percutaneous left atrial appendage closure results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF(PROTECT AF)clinical trial and the Continued Access Registry[J]. Circulation,2011,123(4):417-424.
[18] Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol,2013,61(25):2551-2556.
[19] Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial[J]. J Am Coll Cardiol,2014,64(1):1-12.
[20] Navkaranbir Singh B,Akhil P,Shikhar A,et al. Percutaneousleft atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation:a systematic review and analysis of observational studies[J]. JACC Cardiovasc Interv,2014,7(3):296-304.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[5]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[6]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[7]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[8]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[9]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
　FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
[10]夏平,杨浩.炎症与心房颤动相关性的研究进展[J].心血管病学进展,2015,(5):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
　XIA Ping,YANG Hao.Research Progress of Inflammation Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
[11]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[12]蒋靖波,钟国强.心房颤动导管消融中脑卒中和无症状脑梗死的预防[J].心血管病学进展,2015,(6):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]
　JIANG Jingbo,ZHONG Guoqiang.Strategies to Prevent Periprocedural Stroke and Subclinical Cerebral Emboli in Patients Undergoing Catheter Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]

备注/Memo

备注/Memo:
基金项目:国家重点基础研究发展计划(2014CB542400); 国家自然科学基金面上项目(81170112,81270210); 重庆市科委课题(CSTC2012JJA10143); 国家临床重点专科建设项目经费资助[财社(2011)170号] 作者简介:胡红玲(1990—),住院医师,在读硕士,从事非瓣膜性心房颤动脑卒中防治的研究。Email: 1491684302@qq.com 通信作者:罗素新(1969—),主任医师,教授,博士,从事各种心血管疾病及介入诊疗领域的研究。Email:luosuxin
更新日期/Last Update: 2016-05-25